Comparison of Single and Prolonged Fluoroquinolone Prophylaxis and Risk Factors for Infectious Complications After Transrectal Prostate Biopsy

Abstract

Background: The ideal prophylaxis duration for transrectal ultrasonography-guided prostate biopsy is incompletely defined. Aims: To compare the infectious complications of transrectal ultrasonography-guided prostate biopsy with and without extended antibiotic prophylaxis. The secondary aim was to evaluate the risk factors for infectious complications. Study Design: Prospective observational study. Methods: Four hundred patients who underwent transrectal ultrasonography-guided prostate biopsy were recruited. Patients orally received either 750 mg ciprofloxacin 60 min before the procedure or 500 mg ciprofloxacin twice a day for a duration of 7 days with the initial dose administered 24 h prior to the procedure. All patients were followed-up for 4 weeks after the transrectal ultrasonography-guided prostate biopsy procedure for infectious complications. Screening of urine was carried out in all patients on the 3rd and 7th day after the procedure. Medical histories of all patients were collected prior to biopsy. Information on medical history include the following: hospitalization, urethral catheterization, or urinary tract infections within the past 12 months; antibiotic use within the last 3 months, prior urinary tract interventions, and previous transrectal ultrasonography-guided prostate biopsy and Charlson comorbidity indexes. Ultrasound-guided biopsy was carried out using General Electric’s 7 MHz transrectal ultrasound device in the left decubitus position. Patients received one of the two ciprofloxacin-based prophylaxis regimens. Subsequent transrectal ultrasonography-guided prostate biopsy to all patients were followed-up for 30 days. Further follow-up of patients was carried out on the second and fourth weeks after transrectal ultrasonography-guided prostate biopsy, and symptoms, such as dysuria, rectal bleeding, fever, hematospermia, hematuria, and pollakiuria, were recorded. Results: Both groups presented similar baseline characteristics and medical history. Infectious complication rates within the 4-week follow-up were similar in both groups (single dose: 3% vs prolonged: 3%) (p>0.05). In both groups, infectious complications significantly increased than that at previous antibiotic usage (single: p=0.028; prolonged: p=0.040). Non-infectious complication ratios showed no significant variation (p>0.05). Conclusion: Pre-operative single dose of 750 mg oral ciprofloxacin compared with 7 days prolonged treatment resulted in similar infectious complication outcomes in patients undergoing transrectal ultrasonography-guided prostate biopsy. The use of antibiotics within the last 3 months increases the risk for post-transrectal ultrasonography-guided prostate biopsy infectious complications.

Keywords

• Biopsy, fluoroquinolone, prophylaxis, prostate, urinary tract infections

Kaynakça

1. 1. National Cancer Institute. National Institutes of Health 2016.
2. 2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Cli. 2005;55:74-108.
3. 3. Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study Eur Urol 2013;63:521-7.
4. 4. 4. Bruyère F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet JD, et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol 2015;193:145-50.
5. 5. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85:682-5.
6. 6. Bratzler DW, Houck PM; Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189:395-404.
7. 7. Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL. Singledose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552-8.
8. 8. Çek M, Tandoğdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, et al. Antibiotic prophylaxis in urology departments, 2005-2010. E Urol 2013;63:386-94.

9. 9. Hillelsohn JH, Duty B, Blute ML Jr, Okhunov Z, Kashan M, Moldwin R, et al. Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures. Can J Urol 2012;19:6573-7.
10. 10. Shandera KC, Thibault GP, Deshon GE Jr. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998;52:644-6.
11. 11. Van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14:1722-30.
12. 12. Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al. Targeted Antimicrobial Prophylaxis Using Rectal Swab Cultures in Men Undergoing Transrectal Ultrasound Guided Prostate Biopsy is Associated With Reduced Incidence of Postoperative Infectious Complications and Cost of Care. J Urol 2012;187:1275-9
13. 13. Cam K, Kayikci A, Akman Y, Erol A. Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. Int J Urol 2008;15:997-1001.
14. 14. Briffaux R, Merlet B, Normand G, Coloby P, Leremboure H, Bruyère F, et al. Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomized study. Prog Urol 2009;19:39-46.
15. 15. Liss MA, Chang I, Santos R, Nakama-Peeples A, Peterson EM, Osann K, et al. Prevalence and Significance of Fluoroquinolone Resistant Escherichia coli in Patients Undergoing Transrectal Ultrasound Guided Prostate Needle Biopsy. J Urol 2011;185:1283-8.
16. 16. Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy: should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012;18:575-81.
17. 17. Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 2014;192:1673-8.
18. 18. Tukenmez Tigen E, Tandogdu Z, Ergonul O, Altinkanat G, Gunaydin B, Ozgen M, et al. Outcomes of Fecal Carriage of Extended-spectrum β-Lactamase After Transrectal Ultrasound-guided Biopsy of the Prostate. J Urol 2014;84:1008-15.
19. 19. Tandogdu Z, Bartoletti R, Cai T, Çek M, Grabe M, Kulchavenya E, et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol 2016;34:1193-200.
20. 20. Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and Other Urinary System Infection [USI]) Events: Center of Disease control and prevention, 2016.
21. 21. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.
22. 22. Grabe M, Bartoletti R, Johansen TEB,Cai T, Çek M,Köves B, et al. Guidelines on Urological Infections: European Association of Urology, 2017
23. 23. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71:618-29.
24. 24. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
25. 25. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.
26. 26. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R,et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.
27. 27. Zani EL, Clark OAC, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011:CD006576.
28. 28. Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, et al. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int 2013;111:946-53.